Drugs /

pds0101

Back to Drugs List

Overview

NCI Definition [1]:
A liposomal nanoparticle-based therapeutic vaccine composed of the cationic lipid R-DOTAP (R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride) encapsulating six human papillomavirus 16 (HPV-16) E6 and E7 peptides, with potential immunostimulating activity. Upon subcutaneous administration of the liposomal HPV-16 E6 and E7 multipeptide vaccine, the nanoparticles are taken up by antigen presenting cells (APCs), specifically dendritic cells (DCs), which may stimulate the immune system to induce a cytotoxic T-lymphocyte response (CTL) against HPV-16 E6 and E7-expressing tumor cells. HPV-16 E6 and E7 are oncoproteins that play a key role in the tumorigenesis of a variety of cancers.

Clinical Trials

View Clinical Trials for pds0101

Pds0101 has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating pds0101, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open).

CDKN2A Overexpression, HPV Positive, and PD-L1 Expression (CPS >= 1) are the most frequent biomarker inclusion criteria for pds0101 clinical trials.

Cervical squamous cell carcinoma, head and neck squamous cell carcinoma, and malignant solid tumor are the most common diseases being investigated in pds0101 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pds0101
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pds0101 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
liposomal hpv-16 e6/e7 multipeptide vaccine pds0101, mmunomapk-rdotap /hpv-16 e6/e7 peptide antigen vaccine, immunomapk-rdotap /hpv-16 e6/e7 peptide antigen vaccine, liposomal hpv-16 e6/e7 multipeptide vaccine pds0101
NCIT ID [1]:
C111688

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.